Verification of Risk Factors of Thrombohemorrhagic Complications in Recipients After Related Liver Transplantation (VORTAL)

Verification of Prognostic Risk Factors of Thrombohemorrhagic Complications in Early Follow-up Period in Recipients After Living Related Liver Transplantation

The aim of the study is to improve the results of related transplantation of the right liver lobe by verifying the general predictors of the development of hemostatic system disorders and optimizing a comprehensive program for thrombohemorrhagic complications preventing.

Study Overview

• Status: Recruiting
• Conditions: Liver Cirrhosis; Liver Transplant; Complications
• Intervention / Treatment: Procedure: Liver transplantation

• Study Type: Observational
• Enrollment (Estimated): 30

Contacts and Locations

• Study Contact: Name: Azam Babadjanov, Professor; Phone Number: +998901751703; Email: azambabadjanov@gmail.com

Study Locations

• Uzbekistan
  • Tashkent, Uzbekistan, 100115
    • Recruiting
    • Republican specialized scientific and practical medical center of surgery named after academician V.Vakhidov
    • Contact: Azam Babadjanov, Professor; Phone Number: +998901751703; Email: azam746@mail.ru

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Patients with end stage liver cirrhosis who underwent living related liver transplantation.

Description

Inclusion Criteria:

• Age over 18 years and up to 70 years;
• Signed informed consent for inclusion to the study;
• End stage liver cirrhosis.

Exclusion Criteria:

• Pregnancy;
• Extrahepatic factors influencing systemic hemostasis;
• Concomitant hematological diseases affecting the hemostatic system;
• Severe concomitant disorders.

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
liver transplant group	Procedure: Liver transplantation; Related transplantation of the right lobe of the liver

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Thrombosis of vascular anastomosis	Thrombosis of arterial or venous anastomosis after intervention	1 month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Hemorrhagic complications	Any hemorrhagic complications after intervention	1 month

Collaborators and Investigators

• Sponsor: Republican Specialized Scientific and Practical Medical Center of Surgery Named After V. Vakhidov

Study record dates

Study Major Dates

• Study Start (Actual): April 22, 2022
• Primary Completion (Estimated): November 14, 2026
• Study Completion (Estimated): December 16, 2026

Study Registration Dates

• First Submitted: December 5, 2023
• First Submitted That Met QC Criteria: December 5, 2023
• First Posted (Actual): December 13, 2023

Study Record Updates

• Last Update Posted (Actual): December 30, 2025
• Last Update Submitted That Met QC Criteria: December 29, 2025
• Last Verified: July 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Digestive System Diseases; Liver Diseases; Fibrosis; Pathological Conditions, Signs and Symptoms; Liver Cirrhosis; Therapeutics; Surgical Procedures, Operative; Transplantation; Digestive System Surgical Procedures; Cell- and Tissue-Based Therapy; Biological Therapy; Tissue Transplantation; Organ Transplantation; Liver Transplantation
• Other Study ID Numbers: 05122023

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No